A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment

American Journal of Obstetrics and Gynecology

Volumn 175, Issue 1, 1996, Pages 105-109

  Mukherjee, T ^a   Barad, D ^a   Turk, R ^a   Freeman, R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

bone density; dual energy x ray absorptiometry; etidronate; Gonadotropin releasing hormone agonist

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; ETIDRONIC ACID; GONADORELIN; LEUPRORELIN; PHOSPHORUS;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIOSIS; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERUS MYOMA;

EID: 0029808343     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70258-2     Document Type: Article

References (26)

1. CC Coddington RL Collins TH Shawker Long acting gonadotropin-releasing hormone analog used to treat leiomyomata uteri Fertil Steril 45 1986 624 629
2. A Lemay R Maheux N Faure Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LhRH) agonist (Buserelin) as a new therapeutic approach for endometriosis Fertil Steril 41 1984 863 871
3. M. Damewood Endometriosis and infertility physiologic mechanisms and contemporary therapeutic considerations, including GnRH agonists Semin Reprod Endocrinol 11 1993 1217 1223
4. AJ. Friedman Treatment of uterine myomas with GnRH agonists Semin Reprod Endocrinol 11 1993 154 161
5. MD Damewood WD Schlaff JS Hesla JA. Rock Interval bone mineral density with long-term gonadotropin releasing hormone agonist suppression Fertil Steril 52 1989 596 599
6. JA Gudmundsson IJ Sverker C Bergquist Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition J Clin Endocrinol Metab 65 1987 159 163
7. JC. Gallagher Effect of gonadotropin-releasing hormone agonists on bone metabolism Semin Reprod Endocrinol 11 1993 201 208
8. JS Johansen JB Riis C Hassager M Moen J Jacobsen C. Christiansen The effect of a gonadotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism J Clin Endocrinol Metab 67 1988 701 705
9. ES Surrey N Fournet B Voight HL. Judd Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report Obstet Gynecol 81 1993 581 586
10. AJ Friedman MD. Hornstein Gonadotropin-releasing hormone agonist plus estrogen-progestin “add-back” therapy for endometriosis-related pelvic pain Fertil Steril 60 1993 236 241
11. AJ Frienman RL Barbieri PM Doubilet B Benacerraf R Gleason I. Schiff A randomized, double-blind trial of a gonadotropin-releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri Fertil Steril 49 1988 404 409
12. BR Carr PB Marshburn PT Weatherall KD Bradshaw NA Breslau W. Byrd Effect of GnRH analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double-blind, placebo-controlled, crossover trial J Clin Endocrinol Metab 76 1993 1217 1223
13. AJ Friedman M Daly M Juneau-Norcross MS Rein C Fine R Gleason A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin “Add Back” regimens for women with leiomyomata uteri J Clin Endocrinol Metab 76 1993 1439 1445
14. T Storm G Thamsborg T Steiniche K Genant OH. Sorenson Effect of intermittent cyclic etidronate therapy on bone mass and fracture rate in women with post menopausal osteoporosis N Engl J Med 322 1990 1265 1271
15. NB Watts ST Harris HK Genant RD Wasnich PD Miller RD Jackson Intermittent cyclic etidronate treatment of postmenopausal osteoporosis N Engl J Med 323 1990 73 79
16. GL. Woodson Concurrent therapy with etidronate and estrogen increases bone mass in osteoporosis and osteopenia C Christiansen K Overgaard Osteoporosis 1990. 1990 Osteopress Kobenhavn Copenhagen 1476 1478
17. T Steiniche C Hasling P Charles EF Eriksen F Melsen L. Mosekilde The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and a ADFR regimen Bone 12 1991 155 163
18. H. Fleish Experimental basis for use of bisphosphonates in Paget's disease of bone Clin Orthop 217 1987 72 78
19. J Guncaga T Lauffenburger C Lentner MA Dambacher HG Haas H. Fleisch Bisphosphonate treatment of Paget's disease of bone: a correlated metabolic, calcium kinetic, and morphometric study Horm Metab Res 6 1974 72 78
20. R Freeman T Mukherjee R Turk D. Barad Comparison of DEXA bone density in women with endometriosis or leiomyomata Proceedings of the Fortieth Annual Meeting of the Society for Gynecologic Investigation; 1993 Mar 22-26; Toronto 1993 The Society Toronto
21. RD Jackson ST Harris HK Genant RD Watts AA Wasnich PD Licata Cyclical etidronate treatment of postmenopausal osteoporosis Bone Miner 17 suppl 1 1992 154
22. CH Chestnut HK Genant ST Harris RD Jackson AA Licata PD Miller Etidronate cyclical therapy for treatment of postmenopausal osteoporosis: a 4 year experience J Bone Miner Res 7 suppl 1 1992 143
23. T Storm T Steiniche G Thamsborg F. Melsen Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis J Bone Miner Res 8 1993 199 208
24. P Geusens J Nijs G van der Perre Longitudinal effect of tiludronate on bone mineral density, resonant frequency and strength in monkeys J Bone Miner Res 7 1992 599 609
25. JL Ferretti G Cointry R Capozza E Montuori E Roldan A. Perez Lloret Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats Bone Miner 11 1990 111 122
26. ST Harris NB Watts RD. Jackson Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy Am J Med 95 1993 557 567